Economic Observer reporter Zhang Ling

On July 7th, in a 500 person dealer group, a dealer reminded other dealers in the group that the actual controller of the new industry was detained by supervision, and the brothers who had goods in hand should seize the inventory, monitor bidding, and make preparations in advance.

A day ago, Weng Xianding, the actual controller of the new industry of the in vitro diagnostic company, was detained. New Industry (300832. SZ) announced on the evening of July 6th that it received a notice from the family of the actual controller Weng Xianding on July 6th. According to the "Detention Notice" issued by the relevant supervisory committee, Weng Xianding has been detained. The announcement did not disclose the specific reasons for Weng Xianding's detention and the name of the supervisory committee that made the detention decision.

However, the new industry believes that the detention of the actual controller will not have a significant impact on the company's production and operation. New Industry mentioned in the announcement that Weng Xianding has not held any position in the company since September 8, 2021. As of the announcement, all directors and senior management personnel of the company are performing their duties normally, and the operation and production management of the board of directors are normal. The above matters do not involve the company.

Weng Xianding's resume is quite unique, having served for a long time both inside and outside the system. He once worked in the Finance and Banking Department of the State Development and Reform Commission, and also served as the first special envoy of the State Securities Regulatory Commission in Shenzhen. Later, he entered the business world.

According to the prospectus of the new industry, from July 1986 to September 1992, Weng Xianding worked in the Finance and Banking Department of the State Development and Reform Commission, serving as the Deputy Director of the Finance and Banking Department and the Director of the Securities Department of the Finance and Banking Department. From September 1992 to August 1993, he served as the assistant director of the Shenzhen Planning Bureau and concurrently held the position of the first special envoy of the State Securities Regulatory Commission stationed in Shenzhen. In August 1993, he established New Industry Investment and served as its president. Since 2004, he has served as the Chairman and President of New Industry Investment. Since February 2014, he has served as the executive director of Xizang New Industry. Since August 2012, he has served as a director of New Industry Biotechnology.

Public information shows that Weng Xianding was born in 1961 and is from Hudatang Village, Zhugan Town, Luoshan County, Xinyang, Henan Province. He graduated from the Department of Political Science at Central China Normal University. In 2020, he ranked 166th on the Forbes China 400 list with a wealth of 21.8 billion yuan; In 2024, it ranked 276th on the Hurun Rich List with 18 billion yuan and 1384th on the Hurun Global Rich List with 18.5 billion yuan in assets. He also initiated the establishment of the Xinyang Xianding Education Foundation, which has supported over 2400 impoverished students in his hometown since 2012. In 2023, he donated 100 million yuan to Central China Normal University, setting a record for the highest donation in the university's history.

Public reports show that Weng Xianding has made multiple public appearances recently, including leading a team to Yinchuan on June 21 to investigate Ningxia International Tendering Consulting Group, and on June 22 to inspect the wine producing area on the eastern foot of Helan Mountain.

According to the 2025 annual report of the new industry, Weng Xianding controls approximately 30% of the shares in the new industry.

New Industry is a leading enterprise in the field of in vitro diagnostics in China, with its main products including diagnostic instruments and their supporting diagnostic reagents. It was listed on the Shenzhen Stock Exchange in May 2020. In 2010, New Industry developed the first domestically produced fully automatic chemiluminescence immunoassay analyzer, breaking the monopoly of overseas giants on the Chinese chemiluminescence immunoassay diagnostic market. In the following 16 years, the products of the new industry were sold to 163 countries and regions overseas.

The sales model of the new industry is a combination of distribution and direct sales, with distribution as the main focus. According to the 2025 annual report of New Industry, it has over 3800 active dealers. In 2025, the revenue of new industries is about 4.577 billion yuan, a year-on-year increase of 0.91%, and the net profit is about 1.62 billion yuan, a year-on-year decrease of 11.39%. In the first quarter of 2026, the revenue of new industries was 1.129 billion yuan, a year-on-year increase of 0.34%, and the net profit attributable to the parent company was 442 million yuan, a year-on-year increase of 1.02%.

In the 2025 annual report of New Industries, it was mentioned that in recent years, the National Healthcare Security Administration has continued to promote the reform of centralized and quantity based procurement of drugs and high-value medical consumables. The impact of multiple policies, such as the governance of inspection fees, unbinding inspection packages, and mutual recognition of inspection results, has led to fluctuations in the size of the domestic in vitro diagnostic market, putting pressure on the prices of reagents and gross profit margins in new industries. The new industry is actively increasing its market share and developing more high value-added reagent projects to compensate for the impact of price declines.

On July 6th, the new industry fell 7.52% to 40.97 yuan per share, with a total market value of 32.19 billion yuan; On July 7th, the new industry opened down 6.79%, and as of press time, it fell 2.71% to 39.86 yuan per share, with a total market value of 31.32 billion yuan.